Mesenteric panniculitis is associated with cardiovascular risk-factors: A case-control study



      This study evaluated the prevalence of cardiovascular risk-factors in patients with mesenteric panniculitis.


      To determine whether cardiovascular risk-factors and mesenteric panniculitis are associated.


      Retrospective, matched case-control study of patients referred to Meir Medical Center, Israel, 2014–2019, who underwent computerized tomography scan, were diagnosed mesenteric panniculitis by radiologic criteria. They were compared to two, matched case-control groups: hospitalized patients without mesenteric panniculitis and the general population based on Israeli Ministry of Health surveys. Patients with active malignancy, IBD or significant intra-abdominal morbidity were excluded.


      Of 376 patients with mesenteric panniculitis diagnosed by computerized tomography, 187 were included. Compared to hospital patients, they had higher incidence of dyslipidemia (77.5%/56.7%), hypertension (52.4%/40.6%), obesity (body mass index>30) (60.4%/30.5%) and nonalcoholic fatty liver disease (42.2%/16.6%). Similar differences were observed compared to the general population. In multivariable logistic regression, dyslipidemia, obesity, and nonalcoholic fatty liver disease were independent predictors for mesenteric panniculitis.


      Patients with mesenteric panniculitis have more cardiovascular risk-factors compared to a case-control group and to the general population. This suggests that mesenteric panniculitis is clinically significant and may be part of the metabolic morbidity burden. This association should be further explored.



      NAFLD (nonalcoholic fatty liver disease), MP (Mesenteric panniculitis)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Emory T.S.
        • Monihan J.M.
        • Carr N.J.
        • Sobin L.H
        Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity?.
        Am J Surg Pathol. 1997; 21: 392-398
        • Jura V.Sulla
        mesenterite retratile e sclerosante.
        Policlinico (Sez Chir). 1924;
        • Ogden W.W.
        • Bradburn D.M.
        • Rives J.D
        Pannicultis of the mesentery.
        Ann Surg. 1960; 151: 659-668
        • Green M.S.
        • Chhabra R.
        • Goyal H
        Sclerosing mesenteritis: a comprehensive clinical review.
        Ann Transl Med. 2018; 6: 336
        • Danford C.J.
        • Lin S.C.
        • Wolf J.L
        Sclerosing mesenteritis.
        Am J Gastroenterol. 2019; 114: 867-873
        • Kuhrmeier A
        [Mesenteric lipodystrophy].
        Schweiz Med Wochenschr. 1985; 115: 1218-1224
        • Daskalogiannaki M.
        • Voloudaki A.
        • Prassopoulos P.
        • Magkanas E.
        • Stefanaki K.
        • Apostolaki E.
        • et al.
        CT evaluation of mesenteric panniculitis: prevalence and associated diseases.
        AJR Am J Roentgenol. 2000; 174: 427-431
        • Wilkes A.
        • Griffin N.
        • Dixon L.
        • Dobbs B.
        • Frizelle F.A
        Mesenteric panniculitis: a paraneoplastic phenomenon?.
        Dis Colon Rectum. 2012; 55: 806-809
        • van Putte-Katier N.
        • van Bommel E.F.H.
        • Elgersma O.E.
        • Hendriksz T.R
        Mesenteric panniculitis: prevalence, clinicoradiological presentation and 5-year follow-up.
        Br J Radiol. 2014; 8720140451
        • Gögebakan Ö.
        • Albrecht T.
        • Osterhoff M.A.
        • Reimann A
        Is mesenteric panniculitis truely a paraneoplastic phenomenon? A matched pair analysis.
        Eur J Radiol. 2013; 82: 1853-1859
        • Coulier B
        Mesenteric panniculitis. Part 2: prevalence and natural course: MDCT prospective study.
        JBR-BTR. 2011; 94: 241-246
        • Akram S.
        • Pardi D.S.
        • Schaffner J.A.
        • Smyrk T.C
        Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients.
        Clin Gastroenterol Hepatol. 2007; 5 (quiz 523): 589-596
        • Buragina G.
        • Magenta Biasina A.
        • Carrafiello G
        Clinical and radiological features of mesenteric panniculitis: a critical overview.
        Acta Biomed. 2019; 90: 411-422
        • Coulier B
        Mesenteric panniculitis part 1: MDCT - pictorial review.
        J Belg Soc Radiol. 2011; 94: 229
        • Sharma P.
        • Yadav S.
        • Needham C.M.
        • Feuerstadt P
        Sclerosing mesenteritis: a systematic review of 192 cases.
        Clin J Gastroenterol. 2017; 10: 103-111
        • Protin-Catteau L.
        • Thiéfin G.
        • Barbe C.
        • Jolly D.
        • Soyer P.
        • Hoeffel C
        Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis.
        Acta Radiol. 2016; 57: 1438-1444
        • Schäffler A.
        • Schölmerich J.
        • Büchler C
        Mechanisms of disease: adipocytokines and visceral adipose tissue–emerging role in intestinal and mesenteric diseases.
        Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 103-111
        • Tavares Pereira J.P.
        • Romão V.
        • Eulálio M.
        • Jorge R.
        • Breda F.
        • Calretas S.
        • et al.
        Sclerosing mesenteritis and disturbance of glucose metabolism: a new relationship? A case series.
        Am J Case Rep. 2016; 17: 55-59
        • Unlu E.
        • Okur N.
        • Acay M.B.
        • Kacar E.
        • Ozdinc S.
        • Balcik C.
        • et al.
        The prevalence of incidentally detected idiopathic misty mesentery on multidetector computed tomography: can obesity be the triggering cause?.
        Can Assoc Radiol J. 2016; 67: 212-217
        • Özer Gökaslan Ç.
        • Aslan E.
        • Demirel E.
        • Yücel A
        Relationship of mesenteric panniculitis with visceral and subcutaneous adipose tissue.
        Turk J Med Sci. 2020; 50: 44-48
        • Gunes S.O.
        • Akturk Y.
        • Guldogan E.S.
        • Yilmaz K.B.
        • Ergun O.
        • Hekimoglu B
        Association between mesenteric panniculitis and non-neoplastic disorders.
        Clin Imaging. 2021; 79: 219-224
        • Israel Center for Disease Control (ICDC) S of I
        Israel national health interview survey INHIS-3, 2013–2015: selected findings.
        Israel Center for Disease Control (ICDC), 2017 (Publication no. 374)
        • Coulier B
        Mesenteric panniculitis. Part 1: MDCT–pictorial review.
        JBR-BTR: Organe de La Societe Royale Belge de, 2011
        • Bays H.E
        Adiposopathy is “sick fat” a cardiovascular disease?.
        J Am Coll Cardiol. 2011; 57: 2461-2473
        • Weisberg S.P.
        • McCann D.
        • Desai M.
        • Rosenbaum M.
        • Leibel R.L.
        • Ferrante A.W
        Obesity is associated with macrophage accumulation in adipose tissue.
        J Clin Invest. 2003; 112: 1796-1808
        • Stefan N.
        • Schick F.
        • Häring H.-.U
        Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.
        N Engl J Med. 2014; 371: 2236-2237
        • Rodríguez-Hernández H.
        • Simental-Mendía L.E.
        • Rodríguez-Ramírez G.
        • MA Reyes-Romero
        Obesity and inflammation: epidemiology, risk factors, and markers of inflammation.
        Int J Endocrinol. 2013; 2013678159
        • Greenberg A.S.
        • Obin M.S
        Obesity and the role of adipose tissue in inflammation and metabolism.
        Am J Clin Nutr. 2006; 83: 461S-465S
        • Procaccini C.
        • Jirillo E.
        • Matarese G
        Leptin as an immunomodulator.
        Mol Aspects Med. 2012; 33: 35-45
        • Gangireddy V.G.R.
        • Pilkerton C.
        • Xiang J.
        • Tinajero R.
        • Ashcraft A.M
        Hepatic fibrosis and steatosis in metabolic syndrome.
        J Obes Metab Syndr. 2022;
        • Marchesini G.
        • Bugianesi E.
        • Forlani G.
        • Cerrelli F.
        • Lenzi M.
        • Manini R.
        • et al.
        Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
        Hepatology. 2003; 37: 917-923